Importantly, a recent research pointed out cyclin E overexpression is a mechanism of Trastuzumab resistance in HER2+ breast cancer patients. Thus, co-treatment of trastuzumab with CDK2 inhibitors may be a valid strategy.
Cyclin E overexpression has been identified as a mechanism of resistance to Trastuzumab in HER2-positive breast cancer patients. This suggests that targeting CDK2 inhibitors may be a viable approach to overcome this resistance.